UK Approach to Regulating AI in Life Sciences
The UK is currently navigating the complexities of regulating artificial intelligence (AI) within the life sciences sector. This exploration comes as the government seeks to establish a comprehensive legal framework to replace outdated regulations that were largely influenced by European Union directives. As innovation, particularly in AI, accelerates in the medical device landscape, the regulatory body, the MHRA (Medicines and Healthcare products Regulatory Agency), has begun outlining principles and guidance to govern this rapidly evolving field.
Legislative Position in Great Britain
The UK has been promising new legislation to replace the existing regulatory framework, which is largely based on the now-defunct medical devices directives. While some regulations have been enacted, a complete overhaul is still pending. The MHRA has recognized the urgent need to keep pace with innovation, especially in AI, and has published guiding principles that reflect its current position on software and AI classified as medical devices.
Principles, Not Laws (for Now)
In lieu of comprehensive legislation, the MHRA has developed a set of guiding principles that apply to medical devices incorporating AI. These principles have been shaped in collaboration with global regulatory bodies such as the FDA and Health Canada:
- Ten guiding principles for good machine learning practice to ensure the development of safe, effective, and high-quality AI technologies, updated with an emphasis on transparency in June 2024.
